Potential new treatment may protect celiac patients from gluten-induced injury

The gluten-specific enzyme ALV003 reduces a patient's exposure to gluten and its potential harm, according to a new phase 2 study appearing in Gastroenterology1, the official journal of the American Gastroenterological Association. This study is the first to find that a non-dietary intervention can potentially benefit celiac disease patients.

Study participants were put on an everyday -free diet, challenged with up to 2 grams of gluten daily (equivalent to approximately one half of a standard slice of bread in the U.S.). Researchers found that daily oral administration of ALV003, at the time of gluten ingestion, decreased gluten-induced injury to the small intestine. The treatment appeared to be well tolerated. Gastrointestinal symptoms, such as nausea and abdominal pain, were greater in the placebo group compared with those receiving active treatment.

"Total avoidance of gluten is, at best, challenging," said lead study author, Marja-Leena Lahdeaho, University of Tampere, Tampere University Hospital, Finland. "The potential of ALV003 for is significant given that ongoing exposure to low levels of gluten can cause patients to experience persistent symptoms and , despite following a strict gluten-free diet."

Gluten is widely used in the food and other industries. Cross contamination during food processing is difficult to avoid and the labeling of food products can be inaccurate, misleading or incorrect. The gluten-free diet is socially troublesome, expensive and compliance is problematic. Additionally, traces of gluten can be found in common items such as envelope glue and makeup. These challenges lead to consumption of small amounts of gluten in even the most cautious patients. Thus, there is a need for the development of a pharmacologic therapy that will work with or replace a gluten-free diet.

As the first evidence of a therapeutic intervention for celiac disease meeting primary endpoints, this randomized, double-blind, placebo-controlled clinical trial is a welcomed addition to celiac research. Future studies are warranted before ALV003 can come to market; a 500-person multi-center trial is currently ongoing.

More information: 1. Lähdeaho, Marja-Leena et al. Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease. Gastroenterology 2014; 146(7): 1649 - 1658; www.gastrojournal.org/article/… 0016-5085(14)00242-X

add to favorites email to friend print save as pdf

Related Stories

Top 5 myths about gluten

Jun 06, 2014

In the past few years there has been a surge in gluten-free diets and products that claim giving up the protein can lead to healthier lifestyles. A New York Times article recently cited Mintel, a market research ...

Some 'low-gluten' beer contains high levels of gluten

Dec 21, 2011

Beer tested in a new study, including some brands labeled "low-gluten," contains levels of hordein, the form of gluten present in barley, that could cause symptoms in patients with celiac disease (CD), the ...

Non-celiac gluten sensitivity's existence questioned

Aug 23, 2013

(HealthDay)—There is no evidence that gluten is a trigger in patients with non-celiac gluten sensitivity (NCGS) placed on a low fermentable, oligo-, di-, monosaccharides, and polyols (FODMAP) diet, according ...

Recommended for you

France to receive first Ebola patient

2 hours ago

France on Wednesday prepared to receive its first Ebola patient, as the World Bank warned the spiralling epidemic is threatening economic catastrophe in west Africa.

US scientist: Ebola unlikely to become airborne

3 hours ago

It is unlikely that Ebola would mutate to spread through the air, and the best way to make sure it doesn't is to stop the epidemic, a top U.S. government scientist told concerned lawmakers Wednesday.

User comments